Compare Albemarle Corp. (ALB) vs Biogen Inc (BIIB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Albemarle Corp. vs Biogen Inc — how do they compare? Albemarle Corp. trades at $128.3 (market cap $15.22B), while Biogen Inc trades at $202.49 (market cap $30.37B). The key difference: Biogen Inc is the larger of the two by market cap, and Albemarle Corp. pays a 1.26% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| ALB | BIIB | |
|---|---|---|
Market Cap | $15.22B | $30.37B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $216.63 |
52-Week Low | $67.30 | $122.68 |
Enterprise Value | $18.24B | $32.65B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) is trading at $129.02, down 4.82% over the past 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a low P/E of 5.12 and negative net income margin of -4.24% for 2025, though Q1 2026 earnings beat expectations. Recent news highlights a focus on debt reduction and energy storage system demand as lithium prices rebound. Cash flow improved in 2025 with net cash flow of $425.77 million, while the balance sheet reflects a debt-to-asset ratio of 19.8%.
The outlook for ALB hinges on lithium price recovery and execution in energy storage markets. Analyst consensus is mixed with a $227.10 price target suggesting significant upside, but risks include volatile lithium markets and ongoing profitability challenges. The stock's current level near key support at $128 may attract value investors, though macroeconomic and commodity pressures remain headwinds.
Biogen (BIIB) trades at $205.70, down 4.82% today, with a bullish technical signal and strong earnings beat history. The stock shows solid fundamentals with a P/E of 22.42, net income margin of 13.81%, and positive cash flow trends. Recent acquisitions like RayThera for up to $1 billion aim to expand its immunology pipeline, while Alzheimer's portfolio updates at AAIC 2026 provide near-term catalysts. Analyst consensus is bullish with a $224.82 price target, though legal investigations and legacy drug sales declines pose headwinds.
The outlook remains positive given earnings momentum and strategic pipeline investments, but investors face risks from ongoing legal probes and competitive pressures. The stock offers upside to consensus targets if new drug launches offset revenue declines, but volatility may persist amid sector rotation and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
